Linda Malkas, Ph.D.

Linda Malkas, Ph.D.
Associate Director of Basic Research
Comprehensive Cancer Center
Professor and Associate Chairman of Molecular and Cellular Biology

Dr. Malkas is the Associate Director of Basic Research for City of Hope Comprehensive Cancer Center and Professor and Associate Chairman of Molecular and Cellular Biology. Dr. Malkas received her B.A. in chemistry and Ph.D. in biochemistry from the City University of New York. She completed her post-doctoral studies at the Worchester Foundation for Experimental Biology in Massachusetts, and held faculty positions at the University of Maryland School Of Medicine in Baltimore. Before joining City of Hope, she was at the Indiana University School of Medicine as a Professor of Medicine and the University’s first Vera Bradley Chair in Oncology. While there, she co-founded and served as co-leader of the Indiana University Simon Cancer Center’s Breast Cancer Research Program. She also founded and served as the first Director of the Signature Center for Breast Cancer Research at Indiana University. Dr. Malkas has published more than 75 peer-reviewed publications in respected journals, given many plenary and platform presentations at national and international scientific meetings, and participated in a variety of NIH and DOD grant review study sections. Dr. Malkas is also a member of the Editorial Boards for Cancer Research, Cancer Prevention Research, Current Cancer Therapy Reviews, and the American Journal of Translational Research. Since 2011 she has served on the DOD Ovarian Cancer Research Program Integration Panel. She is also an external advisor for both the Yale University and the University of Texas San Antonio Cancer Centers. In addition, Dr. Malkas is the co-inventor on more than 23 U.S. and international patents and has received multiple awards and recognitions during her career. Dr. Malkas’ major research focus is the relationship between DNA replication and cancer. Her laboratory’s recent work has led to the opportunity to develop truly selective, therapeutic agents that will inhibit proteins uniquely expressed by cancer cells.